Pharmafile Logo

Cluster headaches

- PMLiVE

Eli Lilly promotes Anat Ashkenazi to chief financial officer

Ashkenazi previously served as CFO of Lilly Research Laboratories

- PMLiVE

Lilly partners with GSK and Vir on COVID-19 antibody study

Study will test Lilly's bamlanivimab with GSK/Vir’s VIR-7831

- PMLiVE

Eli Lilly’s COVID-19 antibody combination reduces risk of hospitalisations and death

High-risk patients treated with the two drugs had a 70% reduction in hospitalisation and death

- PMLiVE

Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%

Bamlanivimab-treated care home residents and staff had a significant reduction in COVID-19 risk

- PMLiVE

Lilly partners with Merus on development of bispecific antibodies for cancer

As part of the deal, Merus could receive a total of up to around $1.6bn for three products

- PMLiVE

Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes

Drug demonstrated a 'significant' slowing of cognitive decline

- PMLiVE

Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal

Acquisition includes a number of candidates for neurodegenerative diseases

- PMLiVE

US secures 650,000 additional doses of Lilly’s COVID-19 antibody

This takes the total purchased amount to 950,000 doses

- PMLiVE

Lilly links up with Precision BioSciences in genome editing deal

Precision will receive an upfront cash payment of $100m

- PMLiVE

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

Drug approved for emergency use in combination with Gilead's remdesivir

- PMLiVE

Eli Lilly’s COVID-19 antibody scores FDA emergency use approval

Drug authorised to treat mild-to-moderate COVID-19

- PMLiVE

Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

Earnings were particularly impacted by lower demand for top diabetes drug Trulicity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links